FONAR (FONR) Q3 2025 earnings summary

Executive summary

• Net income for the nine months ended March 31, 2025 was $9.3M on revenues of $77.1M, down from $12.5M net income year-over-year, while Q3 FY2025 net income rose 24% to $3.1M.

• Operating income declined to $10.7M for the nine months, mainly due to increased reserves and higher costs.

• Revenue growth was driven by higher management and other fees, offset by a decrease in patient fee revenue; Q3 FY2025 revenues increased 6% to $27.2M.

• HMCA managed a record 54,612 MRI scans in Q3 FY2025, up 3.4% year-over-year.

• The company operates in MRI equipment manufacturing/service and diagnostic imaging center management.

Financial highlights

• Revenues for the nine months ended March 31, 2025 were $77.1M, nearly flat year-over-year.

• Net income attributable to FONAR was $7.6M for the nine months, down from $9.7M year-over-year.

• Cash and cash equivalents at March 31, 2025 were $54.3M–$54.4M, down from $56.3M at June 30, 2024.

• Working capital increased to $127.1M at March 31, 2025 from $122.5M at June 30, 2024.

• Net book value per common share increased 5% year-over-year to $25.98.

Outlook and guidance

• Management expects continued challenges from reduced reimbursement rates and inflationary pressures.

• HMCA is expanding by adding high-field MRIs to existing facilities and seeking new locations in New York and Florida.

• A new high-field MRI installation in Nassau County, Long Island, is expected to be operational in Q4 FY2025.

• FONAR is focused on expanding scan volumes and improving operational efficiencies, including the rollout of SwiftMR™ software.

• Liquidity is considered sufficient to support operations and capital expenditures for at least the next twelve months.